Cargando…

Clinical Utility of Second-Look FDG PET-CT to Stratify Incomplete Metabolic Response Post (Chemo) Radiotherapy in Oropharyngeal Squamous Cell Carcinoma

SIMPLE SUMMARY: Incomplete imaging response following non-surgical treatment for head and neck cancer is common, and optimal management is uncertain. This single-centre study assessed the value of performing a second PET-CT scan a few months later in patients with uncertain findings initially after...

Descripción completa

Detalles Bibliográficos
Autores principales: Billingsley, Sarah, Iyizoba, Zsuzsanna, Frood, Russell, Vaidyanathan, Sriram, Prestwich, Robin, Scarsbrook, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9856733/
https://www.ncbi.nlm.nih.gov/pubmed/36672413
http://dx.doi.org/10.3390/cancers15020464
Descripción
Sumario:SIMPLE SUMMARY: Incomplete imaging response following non-surgical treatment for head and neck cancer is common, and optimal management is uncertain. This single-centre study assessed the value of performing a second PET-CT scan a few months later in patients with uncertain findings initially after treatment and showed that in most cases, the changes resolved or stayed the same and were not due to residual cancer. This approach could be used to spare unnecessary surgery when there is initial uncertainty. ABSTRACT: Background: Incomplete response on FDG PET-CT following (chemo)radiotherapy (CRT) for head and neck squamous cell carcinoma (HNSCC) hinders optimal management. The study assessed the utility of an interval (second look) PET-CT. Methods: Patients with oropharyngeal squamous cell carcinoma cancer (OPSCC) treated with CRT at a single centre between 2013 and 2020 who underwent baseline, response, and second-look PET-CT were included. Endpoints were conversion rate to complete metabolic response (CMR) and test characteristics of second-look PET-CT. Results: In total, 714 patients with OPSCC underwent PET-CT post-radiotherapy. In total, 88 patients with incomplete response underwent second-look PET-CT a median of 13 weeks (interquartile range 10–15 weeks) after the initial response assessment. In total, 27/88 (31%) second-look PET-CTs showed conversion to CMR, primary tumour CMR in 20/60 (30%), and nodal CMR in 13/37 (35%). In total, 1/34 (3%) with stable tumour/nodal uptake at the second-look PET-CT relapsed. Sensitivity, specificity, positive (PPV), and negative predictive value (NPV) of second-look PET-CT were 95%, 49%, 50%, and 95% for tumour and 92%, 50%, 50%, and 92% for nodes, respectively. Primary tumour progression following CMR occurred in one patient, two patients with residual nodal uptake at second-look PET-CT progressed locoregionally, and one patient developed metastatic disease following CMR in residual nodes. Conclusion: Most patients undergoing second-look PET-CT converted to CMR or demonstrated stable PET signal. NPV was high, suggesting the potential to avoid unnecessary surgical intervention.